Home
>
US Stocks
>
BioXcel Therapeutics Inc
BioXcel Therapeutics Inc
BTAI

BioXcel Therapeutics Inc

$27.041.96%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
27.85
Today Low/High
26.99 / 29.24
52 Week Low/High
$23.07 / $67.74
Market Cap
$668.46M

Company Details

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.
Organisation
BioXcel Therapeutics Inc
Headquaters
New Haven, Connecticut, United States
Employees
50
Industry
Health Technology
CEO
Vimal Mehta

Discover more

Frequently Asked Questions

What is BioXcel Therapeutics Inc share price today

Can Indians buy BioXcel Therapeutics Inc shares?

How can I buy BioXcel Therapeutics Inc shares from India?

Can Fractional shares of BioXcel Therapeutics Inc be purchased?

What are the documents required to start investing in BioXcel Therapeutics Inc stocks?

We are a SEBI registered investement advisor